Evidence map›Paper›PMID 25796139›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Stephanie J Lee, Daniel Wolff, Carrie Kitko, John Koreth, Yoshihiro Inamoto, Madan Jagasia, Joseph Pidala, Attilio Olivieri, Paul J Martin, Donna Przepiorka and 10 more

3 registry-linked trialsAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 214 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03689894 phase1 / phase2terminatednot on this mapstarted 2019, after this paper: background citation

Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant

TypeinterventionalSponsorDartmouth-Hitchcock Medical CenterRan2019 to 2021Enrolled2ConditionsChronic Graft-versus-host-diseaseArmsIbrutinib, Rituximab
NCT04922736 naactive not recruitingnot on this mapstarted 2021, after this paper: background citation

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

TypeinterventionalSponsorUniversity of UtahRan2021 to 2026Enrolled30ConditionsScleroderma, Systemic, Morphea, Graft Vs Host DiseaseArmsUVA-1 Phototherapy
NCT06756061 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease

TypeinterventionalSponsorByung-Sik ChoRan2025 to 2029Enrolled88ConditionsGVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell TransplantationArmsPrednisone + Jakavi(ruxolitinib), Prednisone
3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  15. Trial
  16. Trial
  17. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  18. Trial
  19. Trial
  20. Trial

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Daniel WolffDepartment of Internal Medicine III, University of Regensburg, Regensburg, Germany.
Carrie KitkoDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan.
John KorethDivision of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Madan JagasiaDivision of Hematology-Oncology, Vanderbilt University, Nashville, Tennessee.
Joseph PidalaBlood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.
Attilio OlivieriDepartment of Clinical and Molecular Sciences, University of Ancona, Ancona, Italy.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Donna PrzepiorkaUS Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland.
Iskra PusicDepartment of Medicine, Washington University, St. Louis, Missouri.
Fiona DignanDepartment of Clinical Haematology, University of Manchester, Manchester, United Kingdom.
Sandra A MitchellOutcomes Research Branch, National Cancer Institute, Bethesda, Maryland.
Anita LawitschkaStem Cell Transplant Unit, St. Anna Children's Hospital, Medical University Vienna, Vienna, Austria.
David JacobsohnDivision of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
Anne M HallClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Kirk R SchultzBC Children's Hospital, University of British Columbia, Vancouver, Canada.
Georgia VogelsangJohns Hopkins Oncology Center, Baltimore, Maryland.
Steven PavleticOutcomes Research Branch, National Cancer Institute, Bethesda, Maryland. Electronic address: pavletis@mail.nih.gov.

Funding

Improving Outcomes Assessment in Chronic GVHDR01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2025
$8.3M
NCI NIH HHS R01 CA118953
6 · The paper itself

Abstract

In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement. Provisional definitions of complete response, partial response, and progression were proposed for each organ and for overall outcome. Based on publications over the last 9 years, the 2014 Working Group has updated its recommendations for measures and interpretation of organ and overall responses. Major changes include elimination of several clinical parameters from the determination of response, updates to or addition of new organ scales to assess response, and the recognition that progression excludes minimal, clinically insignificant worsening that does not usually warrant a change in therapy. The response definitions have been revised to reflect these changes and are expected to enhance reliability and practical utility of these measures in clinical trials. Clarification is provided about response assessment after the addition of topical or organ-targeted treatment. Ancillary measures are strongly encouraged in clinical trials. Areas suggested for additional research include criteria to identify irreversible organ damage and validation of the modified response criteria, including in the pediatric population.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAntineoplastic AgentsBiomarkersChildChronic DiseaseClinical Trials as TopicDisease ProgressionGraft vs Host DiseaseHematologic NeoplasmsHumansImmunosuppressive AgentsNational Institutes of Health (U.S.)Remission InductionSurvival AnalysisTerminology as TopicAntineoplastic AgentsBiomarkersImmunosuppressive AgentsAllogeneic hematopoietic cell transplantationChronic graft-versus-host diseaseConsensusGuidelinesResponse criteria

Identifiers

PMID25796139
PMCPMC4744804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.